Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.00

-0.1%

12:06 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9122)	9/14/2003 12:39:43 PM
From: keokalani'nui	Read Replies (1) of 52153

When Cidecin's Phase 3 was announced in one indication (I forget which at the moment; pneumonia or wound?), it barely failed and the company somewhat meekly pointed a finger at sloppy Eastern European data. The street.com body-slammed the company with a bulls-eye headline: 'Drug Flunks Geography Test.' Or something like that. It was a really funny headline but TSC went on to heap excessive disdain on the company. It was a particularly punishing article; and probably shook a lot of investors out at very low prices--even though the drug was showing activity in a couple settings. Plus, it made me reflect whether, in the name of its own mission to sell one more banner ad, the financial media even considers the choice it makes in potentially destroying a company developing an antibiotic or vaccine. I don't recall TSC revisiting the story as it continuously improved. And now look what's happened.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next